Rapa Nui's Lost Contribution to a Billion-Dollar Drug

A potent drug, rapamycin, initially discovered in a soil sample from Easter Island (Rapa Nui) in 1964, has become a cornerstone of modern medicine. This compound, named after the island's Indigenous name, has proven crucial for preventing organ transplant rejection, treating coronary artery disease, and is now explored for its potential against cancer, diabetes, and even aging.

The discovery stemmed from the 1964 Medical Expedition to Easter Island (METEI), a Canadian-led mission. While scientists collected over 200 soil samples, including the one yielding the rapamycin-producing bacteria, the expedition's methodology has been scrutinized. Researchers studied the Rapa Nui people, a predominantly non-white population, without their full input, leading to accusations of scientific colonialism and power imbalance.

Despite rapamycin's immense success, generating billions of dollars, the Rapa Nui people have never received any financial benefit. This situation highlights issues of Indigenous rights and biopiracy, as pharmaceutical companies profited from a discovery originating on Indigenous land. While international agreements now aim to protect such rights, they were not in place during the METEI expedition.

Formally recognizing the Rapa Nui's essential role is crucial for acknowledging their contribution to this medical breakthrough. The narrative surrounding rapamycin's origin underscores the need for a critical examination of systemic biases in biomedical research and what is owed to Indigenous communities whose lands yield blockbuster discoveries.